Replies to post #278923 on Elite Pharmaceuticals Inc (ELTP)

[WeeZuhl]

total nonsense, ever hear of embeda, ever look at the patents that many others had, most notably Oshlack? remember, elite had to squeak around Oshlack's patents to even get issued. Oh, and by the way this ahead of its time technology seems to be a bit problematic (hi Tmax). I prefer my history to be factually correct

Whoa, doc, hold on. I'm not meaning to overstate. I never said it was revolutionary, I said it was before its time. It's a clever tweak of the antagonist concept, just unique enough to qualify for a patent and give a pathway to commercialization. The patent has not been challenged, so who knows how squeaky it really is. But what I was trying to express is that Elite started an ADF company multiple years before OxyContin came out. It would be nine more years until the movie OxyContin Express won the Peabody for documenting the craziness in Florida. By then, Elite had been less than a dime for nearly two years. ADF OxyContin didn't come out until 2010, and before that nobody ever heard of an ADF label. A lot has changed since then. We have a whole new language for describing ADF properties, testing for effectiveness, and certifying the label. My bet here is that it is worth something to have a unique ADF tech that can readily meet the requirements for chewing, snorting, and IV abuse deterrence labels for any opioid agonist and any time-release characteristic (even if it isn't first and isn't revolutionary). I own about one in 500 share of this very cool, very versatile ADF tech, and I'm very much looking forward to seeing how it turns out. Patience, my friend.



P.S. The tmax problem you mention is another one of those unforced errors I like to talk about. Nonetheless, the tmax thing is an issue with the agonist bead, specifically the oxycodone IR bead. It wouldn't be expected to have any effect on the antagonist bead or apply to any other agonist bead. It has nothing to do with Elite's ADF tech.



https://investorshub.advfn.com/boards/read_msg.aspx?message_id=136591415

But the antagonist ADF tech the company was originally based on was way before its time. Even now, with the opioid epidemic in full bloom, we still allow kids to snort non-ADF IR opioids like oxyIR, Norco, and Percocet. It never had a chance in the early 2000's, which was years before anybody ever heard of OxyContin, Hillbilly heroin, or pill mills. If ever there was a time to commercialize the original ADF tech, now is it. Elite has ready-to-go antagonist ADF versions of Norco and Percocet, and as always, the ADF oxyIR version should be ready to go soon. Maybe someday somebody will decide we ought not to let kids snort this crap. After all these years, Elite is ready for that day to be today.

[lasers]

It is Night vs Day different!!!!

Hysterically funny.

total nonsense, ever hear of embeda, ever look at the patents that many others had, most notably Oshlack? remember, elite had to squeak around Oshlack's patents to even get issued.

Purdue's tech is a high temperature, high pressure, hot melt extrusion process to fuse together the agonist and antagonist strands and then cut into pellets

$ELTP's tech is a low temperature, low pressure process where the agonist and antagonists are formed separately on biologically inert pellets to form beads in a fluid bed dryer. The separate beads, agonist and antagonist are then blended together to form the ADF Capsules.

Purdue was wise enough to never go Commercial because they knew the product would always be unstable, wall forces, due to the higher pressure and higher temperature required in a Commercial size hot melt extruder.

Alas Alpharma/King/Pfizer never had a clue of the perils facing Embeda!!!!